Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8251 to 8300 of 8896 results

  1. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  2. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Withdrawn advice

  3. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

    Withdrawn advice

  4. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Withdrawn advice

  5. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  6. Critical limb ischaemia in peripheral vascular disease: intravenous iloprost (ESUOM24)

    April 2019: This evidence summary has been withdrawn because a product containing intravenous iloprost with a marketing authorisation for treating critical limb ischaemia in peripheral vascular disease is now available in the UK.

    Withdrawn advice

  7. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Withdrawn advice

  8. Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

    This evidence summary has been withdrawn because the product has been discontinued in the UK.

    Withdrawn advice

  9. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  10. Transient ischaemic attack: clopidogrel (ESUOM23)

    This evidence summary has been withdrawn and NICE accredited guidance is available from the Royal College of Physicians.

    Withdrawn advice

  11. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Withdrawn advice

  12. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Withdrawn advice

  13. Scleroderma: oral mycophenolate (ESUOM32)

    This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.

    Withdrawn advice

  14. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  15. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  16. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  17. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Withdrawn advice

  18. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  19. Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)

    This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]

    Withdrawn advice

  20. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  21. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Withdrawn advice

  22. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  23. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Withdrawn advice

  24. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  25. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Withdrawn advice

  26. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  27. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  28. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  29. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Withdrawn advice

  30. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  31. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Withdrawn advice

  32. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Withdrawn advice

  33. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  34. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  35. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  36. Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  37. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  38. Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

    This evidence summary has been updated and replaced by NICE guideline NG81.

    Withdrawn advice

  39. Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

    This evidence summary has been updated and replaced by NICE guideline NG130.

    Withdrawn advice

  40. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  41. Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  42. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Withdrawn advice

  43. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  44. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  45. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  46. Clostridium difficile infection: fidaxomicin (ESNM1)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  47. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  48. Acute diarrhoea in adults: racecadotril (ESNM11)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  49. Acute diarrhoea in children: racecadotril as an adjunct to oral rehydration (ESNM12)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  50. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Withdrawn advice